[Diabetes and Heart Failure : Update 2017]

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2017 Apr 12

PMID 28396903

Citations 1

Authors

K Schutt

N Marx

Affiliations

Soon will be listed here.

Abstract

Patients with diabetes mellitus exhibit an increased risk for the development of heart failure. The occurrence of heart failure in patients with diabetes is associated with a poor prognosis. Therapeutic strategies to reduce cardiovascular morbidity and mortality in diabetes have so far mainly focused on the prevention of coronary events but recent data suggest that an early diagnosis of heart failure in diabetes as well as specific therapies could have a major impact on the prognosis for these patients. This article aims to provide a comprehensive overview on the epidemiology, pathophysiology and prognosis of heart failure in diabetes patients and addresses current aspects of heart failure therapy in diabetes as well as diabetes therapy in heart failure patients.

Citing Articles

Time to Death and Its Determinant Factors Among Patients With Chronic Heart Failure in Northwest Ethiopia: A Retrospective Study at Selected Referral Hospitals.

Moyehodie Y, Muluneh M, Belay A, Fenta S Front Cardiovasc Med. 2022; 9:817074.

PMID: 35600464 PMC: 9120604. DOI: 10.3389/fcvm.2022.817074.

References

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View

Dorr R, Muller-Wieland D, Tschoepe D . Diabetes and the heart--a never-ending story. Herz. 2010; 35(3):129. DOI: 10.1007/s00059-010-3343-1. View

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L . Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004; 43(5):771-7. DOI: 10.1016/j.jacc.2003.11.024. View

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

Matsue Y, Suzuki M, Nakamura R, Abe M, Ono M, Yoshida S . Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J. 2011; 75(12):2833-9. DOI: 10.1253/circj.cj-11-0754. View

Ou S, Shih C, Chao P, Chu H, Kuo S, Lee Y . Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med. 2015; 163(9):663-72. DOI: 10.7326/M15-0308. View

Tschoepe D, Dorr R, Muller-Wieland D . Diabetes and the heart-at the edge between upcoming solutions and newly detected problems. Herz. 2012; 37(3):243. DOI: 10.1007/s00059-012-3609-x. View

MacDonald M, Petrie M, Varyani F, Ostergren J, Michelson E, Young J . Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008; 29(11):1377-85. DOI: 10.1093/eurheartj/ehn153. View

10.

Bahrami H, Bluemke D, Kronmal R, Bertoni A, Lloyd-Jones D, Shahar E . Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008; 51(18):1775-83. DOI: 10.1016/j.jacc.2007.12.048. View

11.

Evans J, Doney A, AlZadjali M, Ogston S, Petrie J, Morris A . Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010; 106(7):1006-10. DOI: 10.1016/j.amjcard.2010.05.031. View

12.

Marx N, McGuire D . Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016; 37(42):3192-3200. DOI: 10.1093/eurheartj/ehw110. View

13.

Maisch B, Alter P, Pankuweit S . Diabetic cardiomyopathy--fact or fiction?. Herz. 2011; 36(2):102-15. DOI: 10.1007/s00059-011-3429-4. View

14.

Thrainsdottir I, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K . The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005; 28(3):612-6. DOI: 10.2337/diacare.28.3.612. View

15.

Ryden L, Tschope D, Dorr R . [Diabetes and the heart - revisited]. Herz. 2008; 33(3):169. DOI: 10.1007/s00059-008-3118-0. View

16.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

17.

Nichols G, Gullion C, Koro C, Ephross S, Brown J . The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27(8):1879-84. DOI: 10.2337/diacare.27.8.1879. View

18.

van Melle J, Bot M, de Jonge P, de Boer R, Van Veldhuisen D, Whooley M . Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010; 33(9):2084-9. PMC: 2928369. DOI: 10.2337/dc10-0286. View

19.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

20.

Meier J . GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012; 8(12):728-42. DOI: 10.1038/nrendo.2012.140. View